Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10503517" target="_blank" >RIV/00064165:_____/25:10503517 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/25:10503517

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=08p33_QXod" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=08p33_QXod</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/bjh.70128" target="_blank" >10.1111/bjh.70128</a>

Result language

angličtina

Original language name

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice

Original language description

Diffuse large B-cell lymphoma (DLBCL) is a relatively well treatable disease with long-term cure rates between 60% and 70% following standard front-line immunochemotherapy R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone). Despite recent treatment advances, 30%-40% of DLBCL patients have primary refractory disease or experience a relapse; both associated with inferior survival outcomes. Importantly, none of the currently used prognostic tools can clearly identify these patients. Circulating tumour DNA (ctDNA) is a promising, non-invasive biomarker that has demonstrated prognostic value across multiple cancer types, including DLBCL. Prior studies have shown that ctDNA levels at diagnosis correlate with key DLBCL characteristics, such as clinical stage, serum lactate dehydrogenase (LDH) levels and international prognostic index (IPI) score. Early ctDNA clearance during treatment has been associated with better response rates and superior survival outcomes in DLBCL patients. However, further real-world data as well as randomized clinical trials are needed to support full ctDNA clinical integration for personalized DLBCL therapy. Therefore, we have analysed 44 DLBCL patients (Table S1), all treated with R-CHOP as a first-line chemoimmunotherapy and determined the baseline ctDNA levels and its dynamics using the CAncer Personalized Profiling by deep Sequencing approach and a custom panel of 521 genes. Methodological details are described in Supporting Informatio S1.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

British Journal of Haematology

ISSN

0007-1048

e-ISSN

1365-2141

Volume of the periodical

207

Issue of the periodical within the volume

5

Country of publishing house

GB - UNITED KINGDOM

Number of pages

5

Pages from-to

2135-2139

UT code for WoS article

001567665800001

EID of the result in the Scopus database

2-s2.0-105015404716